Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 16/20 | 0.58 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.41 |
| ▸ | CTSG | P08311 | 1/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3653757 | 0.94 | CMA1 (0.53) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL998232 | 0.93 | CMA1 (0.54) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL999161 | 0.92 | CMA1 (0.57) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| Choline SCHEMBL3238440 | 0.92 | CMA1 (0.51) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL1000094 | 0.91 | CMA1 (0.54) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL1083298 | 0.91 | CMA1 (0.53) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL4139598 | 0.90 | CMA1 (0.60) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL999895 | 0.90 | CMA1 (0.52) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL3651655 | 0.90 | CMA1 (0.56) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL3650588 | 0.89 | CMA1 (0.55) | CMA1PRSS1PRSS2CTSGPRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222431-B2 | Process for synthesizing phosphonic and phosphinic acid compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-07-17 | — | — | US | claimed |
| JP-2011500682-A | — | — | 2011-01-06 | — | — | JP | claimed |
| EP-2211867-A1 | PROCESS FOR SYNTHESIZING PHOSPHONIC AND PHOSPHINIC ACID COMPOUNDS | Janssen Pharmaceutica N.V. (BE) | 2010-08-04 | — | — | EP | claimed |
| EP-2081430-A2 | SALT FORMS OF SUBSTITUTED BENZOTHIENYL COMPOUNDS | Janssen Pharmaceutica, N.V. (BE) | 2009-07-29 | — | — | EP | claimed |
| US-20090124801-A1 | Process for synthesizing phosphonic and phosphinic acid compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-05-14 | — | — | US | claimed |
| WO-2009051746-A1 | PROCESS FOR SYNTHESIZING PHOSPHONIC AND PHOSPHINIC ACID COMPOUNDS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-04-23 | — | — | WO | claimed |
| WO-2008051489-A2 | SALT FORMS OF SUBSTITUTED BENZOTHIENYL COMPOUNDS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-05-02 | — | — | WO | claimed |
| US-20080097110-A1 | Salt forms of substituted benzothienyl compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-04-24 | — | — | US | claimed |
| US-20130131401-A1 | PROCESS FOR THE PREPARATION OF CHYMASE MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2013-05-23 | — | — | US | disclosed |
| US-8378122-B2 | Process for the preparation of chymase modulators | JANSSEN PHARMACEUTICA NV. (BE) | 2013-02-19 | — | — | US | disclosed |
| US-20120309986-A1 | PROCESS FOR THE PREPARATION OF CHYMASE MODULATORS | ANZALONE LUIGI (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120259130-A1 | PROCESS FOR SYNTHESIZING PHOSPHONIC AND PHOSPHINIC ACID COMPOUNDS | ANZALONE LUIGI (US) | 2012-10-11 | — | — | US | disclosed |
| US-8263785-B2 | Process for the preparation of chymase modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-09-11 | — | — | US | disclosed |
| US-8222431-B2 | Process for synthesizing phosphonic and phosphinic acid compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-07-17 | — | — | US | disclosed |
| WO-2009051746-A1 | PROCESS FOR SYNTHESIZING PHOSPHONIC AND PHOSPHINIC ACID COMPOUNDS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-04-23 | — | — | WO | disclosed |
| EP-1982186-A2 | PROCESSING OF SLPI BY CHYMASE | Janssen Pharmaceutica, N.V. (BE) | 2008-10-22 | — | — | EP | disclosed |
| WO-2008051489-A2 | SALT FORMS OF SUBSTITUTED BENZOTHIENYL COMPOUNDS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-05-02 | — | — | WO | disclosed |
| US-20080097110-A1 | Salt forms of substituted benzothienyl compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-04-24 | — | — | US | disclosed |
| WO-2007084397-A2 | PROCESSING OF SLPI BY CHYMASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-26 | — | — | WO | disclosed |
| US-20070166779-A1 | Processing of SLPI by chymase | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124801-A1 | Process for synthesizing phosphonic and phosphinic acid compounds | CMA1, PPA1, CPN1 | CMA1 1/4885PRSS1 72/4885PRSS2 127/4885 |
| US-20130131401-A1 | PROCESS FOR THE PREPARATION OF CHYMASE MODULATORS | CMA1, SERPINB1, CPA3 | CMA1 1/4885PRSS1 4/4885PRSS2 22/4885 |
| US-20080097110-A1 | Salt forms of substituted benzothienyl compounds | SLC10A1, REN, SLC10A6 | CMA1 1104/4885PRSS1 1753/4885PRSS2 2527/4885 |
| US-20120309986-A1 | PROCESS FOR THE PREPARATION OF CHYMASE MODULATORS | CMA1, SERPINB1, CPA3 | CMA1 1/4885PRSS1 4/4885PRSS2 22/4885 |
| US-20120259130-A1 | PROCESS FOR SYNTHESIZING PHOSPHONIC AND PHOSPHINIC ACID COMPOUNDS | CMA1, PPA1, CPN1 | CMA1 1/4885PRSS1 72/4885PRSS2 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.